Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome.
暂无分享,去创建一个
M. Mahler | C. Gonzalez-Rodriguez | R. Mondejar | F. J. Toyos-Sáenz de Miera | F. Fabiani | E. Melguizo-Madrid | N. Zohoury | I. Romero Losquiño | F. Toyos-Sáenz de Miera
[1] Ji-Eun Kim,et al. Clinical performance of anticardiolipin and anti&bgr;2 glycoprotein I antibodies using a new automated chemiluminescent assay: superior thrombotic prediction of combined results measured by two different methods , 2014, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[2] A. Hoxha,et al. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile , 2013, Journal of thrombosis and haemostasis : JTH.
[3] M. Petri,et al. Utility of Antiphosphatidylserine/Prothrombin and IgA Antiphospholipid Assays in Systemic Lupus Erythematosus , 2013, The Journal of Rheumatology.
[4] M. Khamashta,et al. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. , 2012, Autoimmunity reviews.
[5] K. Devreese,et al. Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti‐beta2‐glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome , 2012, International journal of laboratory hematology.
[6] D. Roccatello,et al. Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome , 2012, Annals of the rheumatic diseases.
[7] M. Lockshin,et al. APS ACTION – AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking , 2012, Lupus.
[8] D. Noubouossie,et al. AN AUTOMATED CHEMILUMINESCENCE IMMUNOASSAY MAY DETECT MOSTLY RELEVANT IgG ANTICARDIOLIPIN ANTIBODIES ACCORDING TO REVISED SYDNEY CRITERIA , 2012, Acta clinica Belgica.
[9] L. Bianchi,et al. Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies. , 2012, Clinica chimica acta; international journal of clinical chemistry.
[10] A. Ruffatti,et al. What Have We Learned about Antiphospholipid Syndrome from Patients and Antiphospholipid Carrier Cohorts? , 2012, Seminars in Thrombosis & Hemostasis.
[11] Takao Koike,et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. , 2012, Arthritis and rheumatism.
[12] Kamil Fijorek,et al. BDTcomparator: a program for comparing binary classifiers , 2011, Bioinform..
[13] C. Maas,et al. Immune responses against domain I of β(2)-glycoprotein I are driven by conformational changes: domain I of β(2)-glycoprotein I harbors a cryptic immunogenic epitope. , 2011, Arthritis and rheumatism.
[14] Sabino Iliceto,et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. , 2011, Blood.
[15] A. Tincani,et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. , 2011, Rheumatology.
[16] P. Meroni,et al. Pathogenesis of antiphospholipid syndrome: understanding the antibodies , 2011, Nature Reviews Rheumatology.
[17] P. Groot,et al. Autoantibodies Directed Against Domain I of Beta2-Glycoprotein I , 2011 .
[18] M. Petri,et al. Association of IgA Anti-ß2 Glycoprotein I with Clinical and Laboratory Manifestations of Systemic Lupus Erythematosus , 2011, The Journal of Rheumatology.
[19] A. Tincani,et al. Anti-β2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their ‘innocent’ profile? , 2010, Annals of the rheumatic diseases.
[20] P. D. de Groot,et al. The association between circulating antibodies against domain I of beta2‐glycoprotein I and thrombosis: an international multicenter study , 2009, Journal of thrombosis and haemostasis : JTH.
[21] T. Ortel,et al. Update of the guidelines for lupus anticoagulant detection , 2009, Journal of thrombosis and haemostasis : JTH.
[22] Y. Shoenfeld,et al. Predictive, protective, orphan autoantibodies: the example of anti-phospholipid antibodies. , 2008, Autoimmunity reviews.
[23] Juan de Dios Luna del Castillo,et al. Comparison of the likelihood ratios of two binary diagnostic tests in paired designs , 2007, Statistics in medicine.
[24] Y. Shoenfeld,et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.
[25] G. M. Iverson,et al. Use of Single Point Mutations in Domain I of β2-Glycoprotein I to Determine Fine Antigenic Specificity of Antiphospholipid Autoantibodies1 , 2002, The Journal of Immunology.
[26] J. Reveille,et al. Guidelines for immunologic laboratory testing in the rheumatic diseases: an introduction. , 2002, Arthritis and rheumatism.
[27] G. M. Iverson,et al. The Orientation of β2GPI on the Plate is Important for the Binding of Anti-β2GPI Autoantibodies by ELISA , 2002 .
[28] G. M. Iverson,et al. Anti-β2 glycoprotein I (β2GPI) autoantibodies recognize an epitope on the first domain of β2GPI , 1998 .
[29] C. Chesterman,et al. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). , 1990, Proceedings of the National Academy of Sciences of the United States of America.